Dr. Stephen T. Oh, MD
Hematology (Hematology (Internal Medicine) Physician)
4500 Forest Park Ave, Div Im Hematology, 6th Fl
Saint Louis, MO 63108
- Medicare participating
At a glance
- Medical school
- Northwestern University Feinberg Medical School (2004)
- Years since graduation
- 22
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 80
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2004Medical school: Northwestern University Feinberg Medical School
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
MO license 2010042897
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Barnes Jewish Hospital Saint Louis, MO
- Barnes-Jewish St Peters Hospital Saint Peters, MO
Medical groups
- Washington University (3,029 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 80
- Services billed
- 2,968
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Insertion of needle into vein for collection of blood sample | 121 | 52 |
| Established patient office or other outpatient visit, 30-39 minutes | 38 | 28 |
| Injection of drug or substance under skin or into muscle | 19 | 18 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 18 | 14 |
| Administration of chemotherapy into vein, 1 hour or less | 15 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Jakafi (ruxolitinib phosphate) | 236 |
| Hydroxyurea Other prescribers in Saint Louis, MO | 124 |
| Ojjaara (momelotinib dihydrochloride) | 28 |
| Anagrelide Hcl | 26 |
| Ayvakit (avapritinib) | 24 |
| Besremi (ropeginterferon alfa-2b-njft) | 17 |
| Tasigna (nilotinib hcl) | 14 |
| Ondansetron Odt (ondansetron) Other prescribers in Saint Louis, MO | 14 |
| Allopurinol Other prescribers in Saint Louis, MO | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 40 payments worth $34,444 in total to this clinician.
| Takeda Pharmaceuticals U.S.A., Inc. | $15,711 |
|---|---|
| Incyte Corporation | $11,623 |
| Pharmaessentia USA Corporation | $6,888 |
| GlaxoSmithKline, LLC. | $88.65 |
| Sobi, Inc | $73.58 |
| Novo Nordisk Inc | $24.53 |
| Servier Pharmaceuticals LLC | $20.29 |
| Hema Biologics, LLC | $15.04 |
| Consulting Fee | $31,614 |
|---|---|
| Travel and Lodging | $1,923 |
| Food and Beverage | $899 |
| Education | $8.01 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. Jul 28, 2025 | Consulting Fee | $11,880 |
| Incyte Corporation Apr 10, 2025 | Consulting Fee | $9,590 |
| Pharmaessentia USA Corporation Oct 21, 2025 | Consulting Fee BESREMI · Oncology | $6,664 |
| Takeda Pharmaceuticals U.S.A., Inc. Jun 30, 2025 | Consulting Fee | $3,080 |
| Takeda Pharmaceuticals U.S.A., Inc. Jul 28, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $406 |
| Incyte Corporation May 9, 2025 | Consulting Fee | $400 |
| Incyte Corporation Dec 6, 2025 | Travel and Lodging Jakafi · Hematology/Oncology · travel to Orlando, FL | $331 |
| Incyte Corporation Apr 10, 2025 | Travel and Lodging travel to Irving, TX | $304 |
| Incyte Corporation Apr 9, 2025 | Travel and Lodging travel to Irving, TX | $242 |
| Pharmaessentia USA Corporation Oct 21, 2025 | Travel and Lodging BESREMI · Oncology · travel to Chicago, IL | $194 |
All 18 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. Dec 11, 2025 | Education in-kind | $8.01 |
| Incyte Corporation Dec 6, 2025 | Travel and Lodging Jakafi · Hematology/Oncology · travel to Orlando, FL | $331 |
| Pharmaessentia USA Corporation Oct 21, 2025 | Consulting Fee BESREMI · Oncology | $6,664 |
| Pharmaessentia USA Corporation Oct 21, 2025 | Travel and Lodging BESREMI · Oncology · travel to Chicago, IL | $194 |
| Takeda Pharmaceuticals U.S.A., Inc. Jul 28, 2025 | Consulting Fee | $11,880 |
| Takeda Pharmaceuticals U.S.A., Inc. Jul 28, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $406 |
| Takeda Pharmaceuticals U.S.A., Inc. Jul 28, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $40.28 |
| Takeda Pharmaceuticals U.S.A., Inc. Jul 28, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $8.00 |
| Takeda Pharmaceuticals U.S.A., Inc. Jun 30, 2025 | Consulting Fee | $3,080 |
| Takeda Pharmaceuticals U.S.A., Inc. Jun 30, 2025 | Travel and Lodging travel to MILAN, Italy · in-kind | $85.48 |
| Incyte Corporation May 9, 2025 | Consulting Fee | $400 |
| Incyte Corporation Apr 10, 2025 | Consulting Fee | $9,590 |
| Incyte Corporation Apr 10, 2025 | Travel and Lodging travel to Irving, TX | $304 |
| Incyte Corporation Apr 10, 2025 | Travel and Lodging travel to Irving, TX | $125 |
| Incyte Corporation Apr 10, 2025 | Travel and Lodging travel to Irving, TX | $51.88 |
| Incyte Corporation Apr 10, 2025 | Travel and Lodging travel to Irving, TX | $25.00 |
| Incyte Corporation Apr 9, 2025 | Travel and Lodging travel to Irving, TX | $242 |
| Incyte Corporation Apr 9, 2025 | Travel and Lodging travel to Irving, TX | $110 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 15 industry-funded studies in 2025, from 6 companies. The companies reported $1,114,142 in research payments for these studies, mostly to the institutions running them.
- A Phase 1, Open-Label, Multicenter Study of INCA033989 in Participants With Myeloproliferative Neoplasms
Incyte Corporation - Study name not reported
Pharmaessentia USA Corporation - A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Hematological Malignancies) and Phase 2 (Dose Expansion of CPI0610 with and without Ruxo…
Novartis Pharmaceuticals Corporation - A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI 0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
Novartis Pharmaceuticals Corporation - Study name not reported
Pharmaessentia USA Corporation - This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy or in combination with ruxolitinib in participants wit…
Incyte Corporation - A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis
Incyte Corporation - Study name not reported
Incyte Corporation - Study name not reported
Pharmaessentia USA Corporation - (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
Blueprint Medicines Corporation · Active, not recruiting · NCT03731260
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.